Home » Biocancell Releases Results From Cancer Drug Trial
Biocancell Releases Results From Cancer Drug Trial
Israel’s Biocancell Therapeutics reported successful results of a trial of its BC-819 treatment for ovarian cancer.
The company reported a 50 percent reduction in the protein marker indicating the presence of ovarian cancer and a significant decline in the number of cancer cells in patients, Israeli business daily Globes reported.
BC-819 is intended for those in whom other ovarian cancer treatments have failed and also is intended to treat liver, bladder and spleen cancer.
Upcoming Events
-
07May
-
14May
-
30May